Great Waters Wealth Management Sells 318 Shares of Solventum Co. (NYSE:SOLV)

Great Waters Wealth Management lowered its position in shares of Solventum Co. (NYSE:SOLV) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,872 shares of the company’s stock after selling 318 shares during the period. Great Waters Wealth Management’s holdings in Solventum were worth $388,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. MML Investors Services LLC boosted its holdings in Solventum by 3.2% in the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock valued at $373,000 after purchasing an additional 168 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Solventum by 4.2% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock valued at $346,000 after buying an additional 200 shares in the last quarter. IVC Wealth Advisors LLC boosted its stake in shares of Solventum by 5.0% in the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock valued at $464,000 after buying an additional 318 shares during the period. KKM Financial LLC grew its position in Solventum by 7.9% during the third quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after buying an additional 319 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. increased its stake in Solventum by 69.7% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 891 shares of the company’s stock worth $59,000 after acquiring an additional 366 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SOLV. Piper Sandler upped their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Stifel Nicolaus started coverage on shares of Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective for the company. Mizuho began coverage on shares of Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price on the stock. Wolfe Research began coverage on shares of Solventum in a report on Thursday, September 26th. They set a “peer perform” rating for the company. Finally, Morgan Stanley lifted their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $68.29.

Solventum Price Performance

SOLV opened at $73.60 on Tuesday. The company’s 50 day moving average is $69.16 and its 200-day moving average is $65.85. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.